查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1463157

抗肥胖药物市场、占有率、规模、趋势、产业分析报告：依作用机制、依产品、依分销管道、依地区、依细分市场预测，2024-2032

Anti-Obesity Medication Market Share, Size, Trends, Industry Analysis Report, By Mechanism of Action (Centrally Acting Drugs, Peripherally Acting Drugs); By Product; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 117 Pages | 商品交期: 最快1-2个工作天内

价格

根据Polaris Market Research的最新研究，预计到2032年，全球抗肥胖药物市场规模将达到734.7085亿美元。 该报告提供了对当前市场动态的详细见解，并对未来市场成长进行了分析。

抗肥胖药物可用于改善个人的盈余，特别是当饮食调整和身体活动等生活方式的改变不足以实现和维持健康体重时。 这些药物透过多种机制发挥作用，包括调节新陈代谢、抑制脂肪吸收和抑制食慾。 医疗保健提供者通常会将其开给符合某些标准的患者，例如体重指数 (BMI) 高的患者或患有 2 型糖尿病等肥胖相关健康问题的患者。

受体重管理社会观念变化、全球肥胖率上升以及药物研究进展等因素的影响，抗肥胖药物市场随着时间的推移经历了可变的增长。 最近，由于人们对肥胖相关健康风险的认识不断提高，以及对更有效、更安全的治疗方案的需求，人们对这个市场的兴趣重新燃起。 市场正在见证新药的推出，包括联合疗法，旨在改善减肥效果并最大限度地减少副作用。 此外，医疗保健提供者越来越强调全面的肥胖管理方法，包括生活方式改变、行为介入和药物治疗。

此外，全球肥胖盛行率不断上升以及人们对相关健康风险的认识不断提高，增加了对有效治疗方案的需求。 药物开发技术的进步为引入具有改善的功效和安全性的新药提供了机会。 此外，社会对体重管理态度的改变以及对预防性医疗保健的日益重视预计将推动市场成长。 此外，数位健康解决方案和个人化医疗方法的整合提供了一种根据个别患者的需求量身定制治疗的途径，从而扩大了市场范围。 此外，製药公司和医疗保健提供者之间的策略联盟以及研发投资的增加预计将在这个充满活力和不断变化的市场格局中提供更多商机。

抗肥胖药物市场报告重点

2023 年，週边作用抗肥胖药物部分由于其机制能够改善营养吸收和减少饥饿而占据最大的收入占有率。

到 2023 年，零售药局领域将占据很大的收入占有率。 这些商店为消费者提供方便的药物取得服务，并且通常位于社区内交通便利的位置。

2023年，由于肥胖率高以及政府支持政策等多种因素，北美地区占据了最大的市场占有率。 此外，製药巨头的合併、收购和联盟等策略性举措在塑造竞争格□□局方面发挥着至关重要的作用。

目录

第一章简介

第 2 章执行摘要

第三章研究方法

第四章全球抗肥胖药物市场洞察

  • 抗肥胖药物市场－通路概况
  • 抗肥胖药物市场动态
    • 推动者和机会
      • 肥胖人数增加
      • 儿童肥胖和病态肥胖的发生率不断上升
    • 抑制因素和课题
      • 缺乏长期疗效数据
  • PESTEL 分析
  • 抗肥胖药物市场通路趋势
  • 价值链分析
  • 新冠肺炎 (COVID-19) 影响分析

第 5 章依产品划分的世界市场

  • 主要发现
  • 简介
  • 非官方
  • 核准

第 6 章以行动方式划分的世界市场

  • 主要发现
  • 简介
  • 中枢作用药物
  • 外周作用药物

第 7 章依通路划分的世界市场

  • 主要发现
  • 简介
  • 医院药房
  • 零售药局
  • 其他

第 8 章依地区划分的世界市场

  • 主要发现
  • 简介
    • 2019-2032 年抗肥胖药物市场评估（依地区）
  • 抗肥胖药物市场 - 北美
    • 北美：抗肥胖药物市场（依产品），2019-2032 年
    • 北美：抗肥胖药物市场，依通路划分，2019-2032 年
    • 北美：抗肥胖药物市场（依作用机制），2019-2032 年
    • 抗肥胖药物市场 - 美国
    • 抗肥胖药物市场 - 加拿大
  • 抗肥胖药物市场 - 欧洲
    • 欧洲：抗肥胖药物市场（依产品），2019-2032 年
    • 欧洲：抗肥胖药物市场，依通路划分，2019-2032 年
    • 欧洲：2019-2032 年抗肥胖药物市场（依作用机转）
    • 抗肥胖药物市场 - 英国
    • 抗肥胖药物市场 - 法国
    • 抗肥胖药物市场 - 德国
    • 抗肥胖药物市场 - 义大利
    • 抗肥胖药物市场 - 西班牙
    • 抗肥胖药物市场 - 荷兰
    • 抗肥胖药物市场 - 俄罗斯
  • 抗肥胖药物市场 - 亚太地区
    • 亚太地区：抗肥胖药物市场，分产品，2019-2032 年
    • 亚太地区：抗肥胖药物市场（依通路），2019-2032 年
    • 亚太地区：2019-2032 年抗肥胖药物市场（依作用机转）
    • 抗肥胖药物市场 - 中国
    • 抗肥胖药物市场 - 印度
    • 抗肥胖药物市场 - 马来西亚
    • 抗肥胖药物市场 - 日本
    • 抗肥胖药物市场—印度尼西亚
    • 抗肥胖药物市场－韩国
  • 抗肥胖药物市场 - 中东和非洲
    • 中东和非洲：抗肥胖药物市场（依产品），2019-2032 年
    • 中东与非洲：抗肥胖药物市场，依通路划分，2019-2032 年
    • 中东与非洲：抗肥胖药物市场（依作用机制），2019-2032 年
    • 抗肥胖药物市场－沙乌地阿拉伯
    • 抗肥胖药物市场 - 阿联酋
    • 抗肥胖药物市场 - 以色列
    • 抗肥胖药物市场 - 南非
  • 抗肥胖药物市场 - 拉丁美洲
    • 拉丁美洲：抗肥胖药物市场（依产品），2019-2032 年
    • 拉丁美洲：抗肥胖药物市场，依通路划分，2019-2032 年
    • 拉丁美洲：抗肥胖药物市场（依作用机制），2019-2032 年
    • 抗肥胖药物市场 - 墨西哥
    • 抗肥胖药物市场 - 巴西
    • 抗肥胖药物市场－阿根廷

第九章竞争态势

  • 扩张与收购分析
    • 放大
    • 收购
  • 合作/协作/合约/出版物

第十章公司简介

  • Boehringer Ingelheim International GmbH
  • Currax Pharmaceuticals
  • Gelesis
  • GlaxoSmithKline plc
  • Kintai Therapeutics
  • Novartis AG
  • Novo Nordisk A/S
  • Rhythm Pharmaceuticals, Inc
  • VIVUS LLC
Product Code: PM4814

The global anti-obesity medication market size is expected to reach USD 73,470.85 million by 2032, according to a new study by Polaris Market Research. The report "Anti-Obesity Medication Market Share, Size, Trends, Industry Analysis Report, By Mechanism of Action (Centrally Acting Drugs, Peripherally Acting Drugs); By Product; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Anti-obesity medications are pharmaceutical substances crafted to aid individuals in controlling and reducing their surplus body weight, particularly when lifestyle modifications like dietary adjustments and physical activity alone prove insufficient for attaining and sustaining a healthy weight. These medications can operate through diverse mechanisms, such as modifying metabolism, inhibiting fat absorption, and suppressing appetite. Healthcare providers typically prescribe them to patients meeting specific criteria, such as those with elevated body mass index (BMI) or obesity-related health issues like type 2 diabetes.

The market for anti-obesity medication has experienced variable growth over time, influenced by factors such as shifting societal perceptions regarding weight management, the global escalation in obesity rates, and advancements in pharmaceutical research. In recent times, there has been a resurgence of interest in this market, spurred by heightened awareness of the health hazards linked to obesity and the demand for more efficient and safe treatment options. The market has witnessed the introduction of novel medications, including combination therapies, aimed at improving weight loss outcomes and minimizing adverse effects. Furthermore, healthcare providers are increasingly emphasizing a comprehensive approach to managing obesity, encompassing lifestyle modifications, behavioral interventions, and pharmaceutical treatments.

Additionally, with a rising prevalence of obesity worldwide and an increasing awareness of associated health risks, there is a growing demand for effective treatment options. Advancements in drug development technologies present opportunities for the introduction of novel medications with improved efficacy and safety profiles. Additionally, shifting societal attitudes towards weight management and the growing emphasis on preventive healthcare are expected to drive market growth. Moreover, the integration of digital health solutions and personalized medicine approaches offers avenues for tailoring treatments to individual patient needs, thereby expanding market reach. Furthermore, strategic collaborations between pharmaceutical companies and healthcare providers, as well as increased investment in research and development, are poised to unlock further opportunities in this dynamic and evolving market landscape.

Anti-Obesity Medication Market Report Highlights

In 2023, the peripherally acting anti-obesity drugs segment accounted for the largest revenue share, due to the mechanism's ability to improve nutrient absorption and reduce feelings of hunger.

In 2023, the retail pharmacies segment emerged as the significant revenue share. These outlets provide convenient access to medications for consumers and are commonly located in easily accessible areas within communities.

In 2023, the North American region dominated the largest market share due to various factors, such as the high prevalence of obesity and supportive government policies. Additionally, strategic maneuvers like mergers, acquisitions, and partnerships among pharmaceutical giants play a pivotal role in shaping the competitive landscape.

The global key market players include Boehringer Ingelheim International GmbH, Currax Pharmaceuticals, Gelesis, GlaxoSmithKline plc, Kintai Therapeutics, Novartis AG, Novo Nordisk A/S, Rhythm Pharmaceuticals, Inc., VIVUS LLC.

Polaris Market Research has segmented the Anti-Obesity Medication market report based on mechanism of action, product, distribution channel, and region:

Anti-Obesity Medication, Mechanism of Action Outlook (Revenue - USD Million, 2019 - 2032)

  • Centrally Acting Drugs
  • Peripherally Acting Drugs

Anti-Obesity Medication, Product Outlook (Revenue - USD Million, 2019 - 2032)

  • Off Label
  • Semaglutide (Wegovy)
  • Topiramate (Xenical Alli)
  • Dulaglutide (Trulicity)
  • Liraglutide (Semaglutide (Wegovy))
  • Others
  • Approved
  • Liraglutide (Orlistat)
  • Bupropion-naltrexone (Contrave)
  • Orlistat
  • Alli
  • Xenical
  • Setmelanotide (Imcivree)
  • Tirzepatide (Zepbound)
  • Phentermine-topiramate (Qsymia)
  • Semaglutide (Wegovy

Anti-Obesity Medication, Distribution Channel Outlook (Revenue - USD Million, 2019 - 2032)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Anti-Obesity Medication, Regional Outlook (Revenue - USD Million, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Australia
  • Rest of Asia Pacific
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Anti-Obesity Medication Market Insights

  • 4.1. Anti-Obesity Medication Market - Distribution Channel Snapshot
  • 4.2. Anti-Obesity Medication Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. The increasing incidence of obesity
      • 4.2.1.2. A rise in the occurrence of childhood obesity and morbid obesity
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Lack of long-term effectiveness data
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Anti-Obesity Medication Market Distribution Channel Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Anti-Obesity Medication Market, by Product

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • 5.3. Off Label
    • 5.3.1. Global Anti-Obesity Medication Market, by Off Label, by Region, 2019-2032 (USD Million)
    • 5.3.2. Semaglutide (Wegovy)
      • 5.3.2.1. Global Anti-Obesity Medication Market, by Semaglutide (Wegovy), by Region, 2019-2032 (USD Million)
    • 5.3.3. Topiramate (Xenical Alli)
      • 5.3.3.1. Global Anti-Obesity Medication Market, by Topiramate (Xenical Alli), by Region, 2019-2032 (USD Million)
    • 5.3.4. Dulaglutide (Trulicity)
      • 5.3.4.1. Global Anti-Obesity Medication Market, by Dulaglutide (Trulicity), by Region, 2019-2032 (USD Million)
    • 5.3.5. Liraglutide (Semaglutide (Wegovy))
      • 5.3.5.1. Global Anti-Obesity Medication Market, by Liraglutide (Semaglutide (Wegovy)), by Region, 2019-2032 (USD Million)
    • 5.3.6. Others
      • 5.3.6.1. Global Anti-Obesity Medication Market, by Others, by Region, 2019-2032 (USD Million)
  • 5.4. Approved
    • 5.4.1. Global Anti-Obesity Medication Market, by Approved, by Region, 2019-2032 (USD Million)
    • 5.4.2. Liraglutide (Orlistat)
      • 5.4.2.1. Global Anti-Obesity Medication Market, by Liraglutide (Orlistat), by Region, 2019-2032 (USD Million)
    • 5.4.3. Bupropion-naltrexone (Contrave)
      • 5.4.3.1. Global Anti-Obesity Medication Market, by Bupropion-naltrexone (Contrave), by Region, 2019-2032 (USD Million)
    • 5.4.4. Orlistat
      • 5.4.4.1. Global Anti-Obesity Medication Market, by Orlistat, by Region, 2019-2032 (USD Million)
      • 5.4.4.2. Alli
      • 5.4.4.2.1. Global Anti-Obesity Medication Market, by Alli, by Region, 2019-2032 (USD Million)
      • 5.4.4.3. Xenical
      • 5.4.4.3.1. Global Anti-Obesity Medication Market, by Xenical, by Region, 2019-2032 (USD Million)
    • 5.4.5. Setmelanotide (Imcivree)
      • 5.4.5.1. Global Anti-Obesity Medication Market, by Setmelanotide (Imcivree), by Region, 2019-2032 (USD Million)
    • 5.4.6. Tirzepatide (Zepbound)
      • 5.4.6.1. Global Anti-Obesity Medication Market, by Tirzepatide (Zepbound), by Region, 2019-2032 (USD Million)
    • 5.4.7. Phentermine-topiramate (Qsymia)
      • 5.4.7.1. Global Anti-Obesity Medication Market, by Phentermine-topiramate (Qsymia), by Region, 2019-2032 (USD Million)
    • 5.4.8. Semaglutide (Wegovy)
      • 5.4.8.1. Global Anti-Obesity Medication Market, by Semaglutide (Wegovy), by Region, 2019-2032 (USD Million)

6. Global Anti-Obesity Medication Market, by Mechanism of Action

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • 6.3. Centrally Acting Drugs
    • 6.3.1. Global Anti-Obesity Medication Market, by Centrally Acting Drugs, by Region, 2019-2032 (USD Million)
  • 6.4. Peripherally Acting Drugs
    • 6.4.1. Global Anti-Obesity Medication Market, by Peripherally Acting Drugs, by Region, 2019-2032 (USD Million)

7. Global Anti-Obesity Medication Market, by Distribution Channel

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • 7.3. Hospital Pharmacies
    • 7.3.1. Global Anti-Obesity Medication Market, by Hospital Pharmacies, By Region, 2019-2032 (USD Million)
  • 7.4. Retail Pharmacies
    • 7.4.1. Global Anti-Obesity Medication Market, by Retail Pharmacies, By Region, 2019-2032 (USD Million)
  • 7.5. Others
    • 7.5.1. Global Anti-Obesity Medication Market, by Others, By Region, 2019-2032 (USD Million)

8. Global Anti-Obesity Medication Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Anti-Obesity Medication Market Assessment, By Geography, 2019-2032 (USD Million)
  • 8.3. Anti-Obesity Medication Market - North America
    • 8.3.1. North America: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
    • 8.3.2. North America: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.3.3. North America: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.3.4. Anti-Obesity Medication Market - U.S.
      • 8.3.4.1. U.S.: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.3.4.2. U.S.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.3.4.3. U.S.: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.3.5. Anti-Obesity Medication Market - Canada
      • 8.3.5.1. Canada: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.3.5.2. Canada.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.3.5.3. Canada: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • 8.4. Anti-Obesity Medication Market - Europe
    • 8.4.1. Europe: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
    • 8.4.2. Europe.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.4.3. Europe: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.4.4. Anti-Obesity Medication Market - UK
      • 8.4.4.1. UK: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.4.4.2. UK.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.4.3. UK: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.4.5. Anti-Obesity Medication Market - France
      • 8.4.5.1. France: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.4.5.2. France.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.5.3. France: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.4.6. Anti-Obesity Medication Market - Germany
      • 8.4.6.1. Germany: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.4.6.2. Germany.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.6.3. Germany: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.4.7. Anti-Obesity Medication Market - Italy
      • 8.4.7.1. Italy: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.4.7.2. Italy.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.7.3. Italy: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.4.8. Anti-Obesity Medication Market - Spain
      • 8.4.8.1. Spain: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.4.8.2. Spain.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.8.3. Spain: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.4.9. Anti-Obesity Medication Market - Netherlands
      • 8.4.9.1. Netherlands: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.4.9.2. Netherlands.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.9.3. Netherlands: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.4.10. Anti-Obesity Medication Market - Russia
      • 8.4.10.1. Russia: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.4.10.2. Russia.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.4.10.3. Russia: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • 8.5. Anti-Obesity Medication Market - Asia Pacific
    • 8.5.1. Asia Pacific: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
    • 8.5.2. Asia Pacific.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.5.3. Asia Pacific: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.5.4. Anti-Obesity Medication Market - China
      • 8.5.4.1. China: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.5.4.2. China.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.5.4.3. China: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.5.5. Anti-Obesity Medication Market - India
      • 8.5.5.1. India: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.5.5.2. India.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.5.5.3. India: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.5.6. Anti-Obesity Medication Market - Malaysia
      • 8.5.6.1. Malaysia: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.5.6.2. Malaysia.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.5.6.3. Malaysia: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.5.7. Anti-Obesity Medication Market - Japan
      • 8.5.7.1. Japan: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.5.7.2. Japan.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.5.7.3. Japan: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.5.8. Anti-Obesity Medication Market - Indonesia
      • 8.5.8.1. Indonesia: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.5.8.2. Indonesia.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.5.8.3. Indonesia: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.5.9. Anti-Obesity Medication Market - South Korea
      • 8.5.9.1. South Korea: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.5.9.2. South Korea.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.5.9.3. South Korea: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • 8.6. Anti-Obesity Medication Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
    • 8.6.2. Middle East & Africa.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.6.3. Middle East & Africa: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.6.4. Anti-Obesity Medication Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.6.4.2. Saudi Arabia.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.6.4.3. Saudi Arabia: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.6.5. Anti-Obesity Medication Market - UAE
      • 8.6.5.1. UAE: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.6.5.2. UAE.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.6.5.3. UAE: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.6.6. Anti-Obesity Medication Market - Israel
      • 8.6.6.1. Israel: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.6.6.2. Israel.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.6.6.3. Israel: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.6.7. Anti-Obesity Medication Market - South Africa
      • 8.6.7.1. South Africa: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.6.7.2. South Africa.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.6.7.3. South Africa: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • 8.7. Anti-Obesity Medication Market - Latin America
    • 8.7.1. Latin America: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
    • 8.7.2. Latin America.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
    • 8.7.3. Latin America: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.7.4. Anti-Obesity Medication Market - Mexico
      • 8.7.4.1. Mexico: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.7.4.2. Mexico.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.7.4.3. Mexico: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.7.5. Anti-Obesity Medication Market - Brazil
      • 8.7.5.1. Brazil: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.7.5.2. Brazil.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.7.5.3. Brazil: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
    • 8.7.6. Anti-Obesity Medication Market - Argentina
      • 8.7.6.1. Argentina: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
      • 8.7.6.2. Argentina.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
      • 8.7.6.3. Argentina: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Boehringer Ingelheim International GmbH
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Currax Pharmaceuticals
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Gelesis
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. GlaxoSmithKline plc
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Kintai Therapeutics
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Novartis AG
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Novo Nordisk A/S
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Rhythm Pharmaceuticals, Inc
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. VIVUS LLC
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development

List of Tables

  • Table 1 Global Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 2 Global Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 3 Global Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 4 Anti-Obesity Medication Market Assessment, By Geography, 2019-2032 (USD Million)
  • Table 5 North America: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 6 North America: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 7 North America: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 8 U.S.: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 9 U.S.: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 10 U.S.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 11 Canada: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 12 Canada: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 13 Canada: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 14 Europe: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 15 Europe: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 16 Europe: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 17 UK: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 18 UK: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 19 UK: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 20 France: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 21 France: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 22 France: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 23 Germany: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 24 Germany: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 25 Germany: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 26 Italy: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 27 Italy: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 28 Italy: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 29 Spain: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 30 Spain: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 31 Spain: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 32 Netherlands: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 33 Netherlands: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 34 Netherlands: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 35 Russia: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 36 Russia: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 37 Russia: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 38 Asia Pacific: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 39 Asia Pacific: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 40 Asia Pacific: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 41 China: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 42 China: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 43 China: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 44 India: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 45 India: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 46 India: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 47 Malaysia: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 48 Malaysia: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 49 Malaysia: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 50 Japan: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 51 Japan: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 52 Japan: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 53 Indonesia: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 54 Indonesia: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 55 Indonesia: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 56 South Korea: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 57 South Korea: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 58 South Korea: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 59 Middle East & Africa: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 60 Middle East & Africa: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 61 Middle East & Africa: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 62 Saudi Arabia: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 63 Saudi Arabia: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 64 Saudi Arabia: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 65 UAE: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 66 UAE: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 67 UAE: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 68 Israel: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 69 Israel: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 70 Israel: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 71 South Africa: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 72 South Africa: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 73 South Africa: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 74 Latin America: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 75 Latin America: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 76 Latin America: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 77 Mexico: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 78 Mexico: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 79 Mexico: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 80 Brazil: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 81 Brazil: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 82 Brazil: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 83 Argentina: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
  • Table 84 Argentina: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
  • Table 85 Argentina: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)

List of Figures

  • Figure 1. Global Anti-Obesity Medication Market, 2019-2032 (USD Million)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Mechanism of Action
  • Figure 7. Global Anti-Obesity Medication Market, by Mechanism of Action, 2022 & 2032 (USD Million)
  • Figure 8. Market by Product
  • Figure 9. Global Anti-Obesity Medication Market, by Product, 2022 & 2032 (USD Million)
  • Figure 10. Market by Distribution Channel
  • Figure 11. Global Anti-Obesity Medication Market, by Distribution Channel, 2022 & 2032 (USD Million)
  • Figure 12. Anti-Obesity Medication Market Assessment, By Geography, 2019-2032 (USD Million)
  • Figure 13. Strategic Analysis - Anti-Obesity Medication Market